Toll-like receptor signaling pathways - Therapeutic opportunities

Mediators of Inflammation

Volumn 2010, Issue , 2010, Pages

  Mohan, Chandra ^a   Zhu, Jiankun ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; HEME OXYGENASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 2; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK1 PROTEIN, HUMAN; MYD88 PROTEIN, HUMAN;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; BACTERIAL INFECTION; CARCINOGENESIS; CYTOKINE PRODUCTION; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; GENETICS; IMMUNOLOGY; NEOPLASM; PHYSIOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASMS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 78349255916     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2010/781235     Document Type: Review

References (66)

1. Barton G. M., Kagan J. C., A cell biological view of Toll-like receptor function: regulation through compartmentalization Nature Reviews Immunology 2009 9 8 535 542
2. Medzhitov R., Preston-Hurlburt P., Janeway C. A. Jr., A human homologue of the Drosophila Toll protein signals activation of adaptive immunity Nature 1997 388 6640 394 397
3. O'Neill L. A. J., The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress Immunological Reviews 2008 226 1 10 18
4. Leadbetter E. A., Rifkin I. R., Hohlbaum A. M., Beaudette B. C., Shlomchik M. J., Marshak-Rothstein A., Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors Nature 2002 416 6881 603 607
5. Sato S., Sugiyama M., Yamamoto M., Watanabe Y., Kawai T., Takeda K., Akira S., Toll/IL-1 receptor domain-containing adaptor inducing IFN- (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF- B and IFN-regulatory factor-3, in the Toll-like receptor signaling Journal of Immunology 2003 171 8 4304 4310
6. Fischer M., Ehlers M., Toll-like receptors in autoimmunity Annals of the New York Academy of Sciences 2008 1143 21 34
7. Oshiumi H., Matsumoto M., Funami K., Akazawa T., Seya T., TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon- induction Nature Immunology 2003 4 2 161 167
8. Fitzgerald K. A., McWhirter S. M., Faia K. L., Rowe D. C., Latz E., Golenbock D. T., Coyle A. J., Liao S.-M., Maniatis T., IKKE and TBKI are essential components of the IRF3 signalling pathway Nature Immunology 2003 4 5 491 496
9. Honda K., Yanai H., Mizutani T., Negishi H., Shimada N., Suzuki N., Ohba Y., Takaoka A., Yeh W.-C., Taniguchi T., Role of a transductional- transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling Proceedings of the National Academy of Sciences of the United States of America 2004 101 43 15416 15421
10. Li S., Strelow A., Fontana E. J., Wesche H., IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase Proceedings of the National Academy of Sciences of the United States of America 2002 99 8 5567 5572
11. Janssens S., Beyaert R., Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members Molecular Cell 2003 11 2 293 302
12. Thomas J. A., Allen J. L., Tsen M., Dubnicoff T., Danao J., Liao X. C., Cao Z., Wasserman S. A., Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase Journal of Immunology 1999 163 2 978 984
13. Uematsu S., Sato S., Yamamoto M., Hirotani T., Kato H., Takeshita F., Matsuda M., Coban C., Ish K. J. II, Kawai T., Takeuchi O., Akira S., Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon- induction Journal of Experimental Medicine 2005 201 6 915 923
14. Ropert C., Franklin B. S., Gazzinelli R. T., Role of TLRs/MyD88 in host resistance and pathogenesis during protozoan infection: lessons from malaria Seminars in Immunopathology 2008 30 1 41 51
15. von Bernuth H., Picard C., Jin Z., Pankla R., Xiao H., Ku C.-L., Chrabieh M., Mustapha I. B., Ghandil P., Camcioglu Y., Vasconcelos J., Sirvent N., Guedes M., Vitor A. B., Herrero-Mata M. J., Arstegui J. I., Rodrigo C., Alsina L., Ruiz-Ortiz E., Juan M., Fortuny C., Yage J., Antn J., Pascal M., Chang H.-H., Janniere L., Rose Y., Garty B.-Z., Chapel H., Issekutz A., Mardi L., Rodriguez-Gallego C., Banchereau J., Abel L., Li X., Chaussabel D., Puel A., Casanova J.-L., Pyogenic bacterial infections in humans with MyD88 deficiency Science 2008 321 5889 691 696
16. Bfica A., Scanga C. A., Schito M., Chaussabel D., Sher A., Influence of coinfecting pathogens on HIV expression: evidence for a role of Toll-like receptors Journal of Immunology 2004 172 12 7229 7234
17. Baenziger S., Heikenwalder M., Johansen P., Schlaepfer E., Hofer U., Miller R. C., Diemand S., Honda K., Kundig T. M., Aguzzi A., Speck R. F., Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology Blood 2009 113 2 377 388
18. Weighardt H., Kaiser-Moore S., Vabulas R. M., Kirschning C. J., Wagner H., Holzmann B., Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection Journal of Immunology 2002 169 6 2823 2827
19. Suzuki N., Suzuki S., Duncan G. S., Millar D. G., Wada T., Mirtsos C., Takada H., Wakeham A., Itie A., Li S., Penninger J. M., Wesche H., Ohashi P. S., Mak T. W., Yeh W.-C., Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4 Nature 2002 416 6882 750 756
20. Ferwerda B., Alonso S., Banahan K., McCall M. B. B., Giamarellos- Bourboulis E. J., Ramakers B. P., Mouktaroudi M., Fain P. R., Izagirre N., Syafruddin D., Cristea T., Mockenhaupt F. P., Troye-Blomberg M., Kumpf O., Maiga B., Dolo A., Doumbo O., Sundaresan S., Bedu-Addo G., Van Crevel R., Hamann L., Oh D.-Y., Schumann R. R., Joosten L. A. B., De La Ra C., Sauerwein R., Drenth J. P. H., Kullberg B.-J., Van Der Ven A. J. A. M., Hill A. V., Pickkers P., Van Der Meer J. W. M., O'Neill L. A. J., Netea M. G., Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock Proceedings of the National Academy of Sciences of the United States of America 2009 106 25 10272 10277
21. Frazier W. J., Wang X., Wancket L. M., Li X.-A., Meng X., Nelin L. D., Cato A. C. B., Liu Y., Increased inflammation, impaired bacterial clearance, and metabolic disruption after gram-negative sepsis in Mkp-1-deficient mice Journal of Immunology 2009 183 11 7411 7419
22. Chi H., Flavell R. A., Acetylation of MKP-1 and the control of inflammation Science Signaling 2008 41, article 44
23. Naiki Y., Michelsen K. S., Schrder N. W. J., Alsabeh R., Slepenkin A., Zhang W., Chen S., Wei B., Bulut Y., Wong M. H., Peterson E. M., Arditi M., MyD88 is pivotal for the early inflammatory response and subsequent bacterial clearance and survival in a mouse model of Chlamydia pneumoniae pneumonia Journal of Biological Chemistry 2005 280 32 29242 29249
24. Huang B., Zhao J., Li H., He K.-L., Chen Y., Mayer L., Unkeless J. C., Xiong H., Toll-like receptors on tumor cells facilitate evasion of immune surveillance Cancer Research 2005 65 12 5009 5014
25. Kelly M. G., Alvero A. B., Chen R., Silasi D.-A., Abrahams V. M., Chan S., Visintin I., Rutherford T., Mor G., TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer Cancer Research 2006 66 7 3859 3868
26. Rakoff-Nahoum S., Medzhitov R., Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88 Science 2007 317 5834 124 127
27. Stevens V. L., Hsing A. W., Talbot J. T., Zheng S. L., Sun J., Chen J., Thun M. J., Xu J., Calle E. E., Rodriguez C., Genetic variation in the Toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk International Journal of Cancer 2008 123 11 2644 2650
28. Droemann D., Albrecht D., Gerdes J., Ulmer A. J., Branscheid D., Vollmer E., Dalhoff K., Zabel P., Goldmann T., Human lung cancer cells express functionally active Toll-like receptor 9 Respiratory Research 2005 6, article 6
29. Henault M., Lee L. N., Evans G. F., Zuckerman S. H., The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides Journal of Immunological Methods 2005 300 1-2 93 99
30. Lee J.-W., Choi J.-J., Eun S. S., Mi J. K., Woo Y. K., Chel H. C., Kim T.-J., Kim B.-G., Sang Y. S., Bae D.-S., Increased Toll-like receptor 9 expression in cervical neoplasia Molecular Carcinogenesis 2007 46 11 941 947
31. Jukkola-Vuorinen A., Rahko E., Vuopala K. S., Desmond R., Lehenkari P. P., Harris K. W., Selander K. S., Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer Journal of Innate Immunity 2008 1 1 59 68
32. Visnen M.-R., Visnen T., Jukkola-Vuorinen A., Vuopala K. S., Desmond R., Selander K. S., Vaarala M. H., Expression of Toll-like receptor-9 is increased in poorly differentiated prostate tumors Prostate 2010 70 8 817 824
33. Ren T., Xu L., Jiao S., Wang Y., Cai Y., Liang Y., Zhou Y., Zhou H., Wen Z., TLR9 signaling promotes tumor progression of human lung cancer cell in vivo Pathology and Oncology Research 2009 15 623 630
34. Xu L., Wang C., Wen Z., Yao X., Liu Z., Li Q., Wu Z., Xu Z., Liang Y., Ren T., Selective up-regulation of CDK2 is critical for TLR9 signaling stimulated proliferation of human lung cancer cell Immunology Letters 2009 127 93 99
35. Baines J., Celis E., Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides Clinical Cancer Research 2003 9 7 2693 2700
36. Krieg A. M., Toll-like receptor 9 (TLR9) agonists in the treatment of cancer Oncogene 2008 27 2 161 167
37. Weigel B. J., Rodeberg D. A., Krieg A. M., Blazar B. R., CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma Clinical Cancer Research 2003 9 8 3105 3114
38. Pashenkov M., Goss G., Wagner C., Hrmann M., Jandl T., Moser A., Britten C. M., Smolle J., Koller S., Mauch C., Tantcheva-Poor I., Grabbe S., Loquai C., Esser S., Franckson T., Schneeberger A., Haarmann C., Krieg A. M., Stingl G., Wagner S. N., Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma Journal of Clinical Oncology 2006 24 36 5716 5724
39. Molenkamp B. G., Van Leeuwen P. A. M., Meijer S., Sluijter B. J. R., Wijnands P. G. J. T. B., Baars A., Van Den Eertwegh A. J. M., Scheper R. J., De Gruijl T. D., Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients Clinical Cancer Research 2007 13 10 2961 2969
40. Link B. K., Ballas Z. K., Weisdorf D., Wooldridge J. E., Bossler A. D., Shannon M., Rasmussen W. L., Krieg A. M., Weiner G. J., Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma Journal of Immunotherapy 2006 29 5 558 568
41. Abdollahi-Roodsaz S., Joosten L. A. B., Roelofs M. F., Radstake T. R. D. J., Matera G., Popa C., Van Der Meer J. W. M., Netea M. G., Van Den Berg W. B., Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis Arthritis and Rheumatism 2007 56 9 2957 2967
42. Roelofs M. F., Wenink M. H., Toonen E. J. M., Coenen M. J. H., Joosten L. A. B., Van Den Berg W. B., Van Riel P. L. C. M., Radstake T. R. D. J., The functional variant (Asp299gly) of Toll-like receptor 4 (TLR4) influences TLR4-mediated cytokine production in rheumatoid arthritis Journal of Rheumatology 2008 35 4 558 561
43. Tsui F. W. L., Xi N., Rohekar S., Riarh R., Bilotta R., Hing W. T., Inman R. D., Toll-like receptor 2 variants are associated with acute reactive arthritis Arthritis and Rheumatism 2008 58 11 3436 3438
44. Snchez E., Orozco G., Lpez-Nevot M.., Jimnez-Alonso J., Martn J., Polymorphisms of Toll-like receptor 2 and 4 genes in rheumatoid arthritis and systemic lupus erythematosus Tissue Antigens 2004 63 1 54 57
45. Lartigue A., Colliou N., Calbo S., Franois A., Jacquot S., Arnoult C., Tron F., Gilbert D., Musette P., Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus Journal of Immunology 2009 183 10 6207 6216
46. Lau C. M., Broughton C., Tabor A. S., Akira S., Flavell R. A., Mamula M. J., Christensen S. R., Shlomchik M. J., Viglianti G. A., Rifkin I. R., Marshak-Rothstein A., RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement Journal of Experimental Medicine 2005 202 9 1171 1177
47. Pisitkun P., Deane J. A., Difilippantonio M. J., Tarasenko T., Satterthwaite A. B., Bolland S., Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication Science 2006 312 5780 1669 1672
48. Subramanian S., Tus K., Li Q.-Z., Wang A., Tian X.-H., Zhou J., Liang C., Bartov G., McDaniel L. D., Zhou X. J., Schultz R. A., Wakeland E. K., A Tlr7 translocation accelerates systemic autoimmunity in murine lupus Proceedings of the National Academy of Sciences of the United States of America 2006 103 26 9970 9975
49. Sadanaga A., Nakashima H., Akahoshi M., Masutani K., Miyake K., Igawa T., Sugiyama N., Niiro H., Harada M., Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice Arthritis and Rheumatism 2007 56 5 1618 1628
50. Su S. B., Silver P. B., Grajewski R. S., Agarwal R. K., Tang J., Chan C.-C., Caspi R. R., Essential role of the MyD88 pathway, but nonessential roles of TLRs 2, 4, and 9, in the adjuvant effect promoting Th1-mediated autoimmunity Journal of Immunology 2005 175 10 6303 6310
51. Adachi O., Kawai T., Takeda K., Matsumoto M., Tsutsui H., Sakagami M., Nakanishi K., Akira S., Targeted disruption of the MyD88 gene results in loss of IL-1- and IL- 18-mediated function Immunity 1998 9 1 143 150
52. Deng C., Radu C., Diab A., Tsen M. F., Hussain R., Cowdery J. S., Racke M. K., Thomas J. A., IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity Journal of Immunology 2003 170 6 2833 2842
53. Jacob C. O., Zhu J., Armstrong D. L., Yan M., Han J., Zhou X. J., Thomas J. A., Reiff A., Myones B. L., Ojwang J. O., Kaufman K. M., Klein-Gitelman M., McCurdy D., Wagner-Weiner L., Silverman E., Ziegler J., Kelly J. A., Merrill J. T., Harley J. B., Ramsey-Goldman R., Vila L. M., Bae S.-C., Vyse T. J., Gilkeson G. S., Gaffney P. M., Moser K. L., Langefeld C. D., Zidovetzki R., Mohan C., Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus Proceedings of the National Academy of Sciences of the United States of America 2009 106 15 6256 6261
54. Tzima S., Victoratos P., Kranidioti K., Alexiou M., Kollias G., Myeloid heme oxygenase-1 regulates innate immunity and autoimmunity by modulating IFN- production Journal of Experimental Medicine 2009 206 5 1167 1179
55. O'Neill L. A. J., Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases Current Opinion in Pharmacology 2003 3 4 396 403
56. Loiarro M., Capolunghi F., Fant N., Gallo G., Campo S., Arseni B., Carsetti R., Carminati P., De Santis R., Ruggiero V., Sette C., Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound Journal of Leukocyte Biology 2007 82 4 801 810
57. Bartfai T., Behrens M. M., Gaidarova S., Pemberton J., Shivanyuk A., Rebek J. Jr., A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses Proceedings of the National Academy of Sciences of the United States of America 2003 100 13 7971 7976
58. Wang Z., Liu J., Sudom A., Ayres M., Li S., Wesche H., Powers J. P., Walker N. P. C., Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper Structure 2006 14 12 1835 1844
59. Song K. W., Talamas F. X., Suttmann R. T., Olson P. S., Barnett J. W., Lee S. W., Thompson K. D., Jin S., Hekmat-Nejad M., Cai T. Z., Manning A. M., Hill R. J., Wong B. R., The kinase activities of interleukin-1 receptor associated kinase (IRAK)-1 and 4 are redundant in the control of inflammatory cytokine expression in human cells Molecular Immunology 2009 46 7 1458 1466
60. Barrat F. J., Meeker T., Gregorio J., Chan J. H., Uematsu S., Akira S., Chang B., Duramad O., Coffman R. L., Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus Journal of Experimental Medicine 2005 202 8 1131 1139
61. Barrat F. J., Meeker T., Chan J. H., Guiducci C., Coffmann R. L., Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms European Journal of Immunology 2007 37 12 3582 3586
62. Pawar R. D., Ramanjaneyulu A., Kulkarni O. P., Lech M., Segerer S., Anders H.-J., Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus Journal of the American Society of Nephrology 2007 18 6 1721 1731
63. Prinz M., Garbe F., Schmidt H., Mildner A., Gutcher I., Wolter K., Piesche M., Schroers R., Weiss E., Kirschning C. J., Rochford C. D. P., Brck W., Becher B., Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis Journal of Clinical Investigation 2006 116 2 456 464
64. Zhu F. G., Evaluation of a DNA-based Toll like receptor antagonist for treatment of collagen induced arthritis in DBA/1 mice Proceedings of the 4th Annual Meeting of the Oligonucleotide Therapeutics Society October 2008 Boston, Mass, USA
65. Zhu F. G., Yu D., Kandimalla E. R., Agrawal S., Studies of combination of IMO-3100, an antagonist of TLR7 and TLR9, and etanercept, a TNF-a inhibitor, in a mouse model of collagen-induced arthritis Proceedings of the Annual Meeting of American College of Rheumaology October 2009
66. Visentini M., Conti V., Cagliuso M., Tinti F., Siciliano G., Trombetta A. C., Mitterhofer A. P., Fiorilli M., Quinti I., Regression of systemic lupus erythematosus after development of an acquired Toll-like receptor signaling defect and antibody deficiency Arthritis and Rheumatism 2009 60 9 2767 2771